In this special throwback episode, John Hovanesian, MD, and Jim Mazzo revisit their discussions with Steven Schwartz, MD, and Sean Ianculev, MD, about innovations, treatments and entrepreneurship in eye care.

• Welcome to the Eyeluminaries podcast :10
• About Steven Schwartz, MD 2:32
• The interview 3:16
• Discussion of current innovation in cataract surgery including use of AI, imaging and robotics 4:05
• Discussion on Schwartz’s involvement in Neurotech MacTel cell-based treatment 6:32
• Advances and disappointments in retinal disease treatments? 10:32
• How do companies come back from disappointing trial results? 11:07
• Why do retina discoveries take so long to develop? 14:31
• New dry AMD treatments in development? 15:58 
• Drug delivery technologies and will retina specialists use them?
• What do you predict we’ll be doing differently in medicine 2 years from now and why? 22:00
• What’s the difference between a retina and cornea specialist? 23:52
• Introduction of Sean Ianchulev, MD, MPH 25:38
• The interview 26:29
• Impact on Google Glass 30:27
• What innovations are you proud of and what projects are you excited about? 35:31
• What advice do you have for new entrepreneurs? 42:16
• How do you balance your work life and your home life? 45:25
• Legends in the field of ophthalmology 47:39
• Give feedback at [email protected] 49:36
• Thanks for listening 49:57

Sean Ianchulev, MD, MPH, is a Harvard-trained physician-scientist, a professor of ophthalmology and the head of innovation and technology at New York Eye and Ear Infirmary founder and chairman of Iantrek Inc and Eyenovia and serves as a board member for the American Society of Cataract and Refractive Surgery Foundation and AEYE Health.

John A. Hovanesian, MD, FACS, is a faculty member at the UCLA Jules Stein Eye Institute and in private practice at Harvard Eye Associates in Laguna Hills, California.

Jim Mazzo sits on numerous ophthalmic industry corporate boards and committees after serving in executive roles with Allergan, Avellino Labs, Carl Zeiss and AMO.

Steven Schwartz, MD, is the Ahmanson professor in ophthalmology and the chief of the retina division at the UCLA Jules Stein Eye Institute and the director of the Diabetic Eye Disease and Retinal Vascular Center.

We’d love to hear from you! Send your comments/questions to [email protected]. Follow John Hovanesian on Twitter @DrHovanesian. You can reach Dr. Schwartz via email at [email protected]. You can find Dr. Ianchulev on LinkedIn. 

Disclosures: Hovanesian consults widely in the ophthalmic field. Mazzo reports being an adviser for Zeiss, Bain Capital, Avellino Labs, CVC Capital, Anivive Lifesciences; executive chairman of Neurotech, Preceyes BV and TearLab; and sits on the board of Crystilex, Lensgen, IanTech, Centricity Vision and Visus. Schwartz is the co-founder of Horizon Surgical; member on the National Eye Institute Audacious Initiative Scientific executive committee and reports receiving grants from Neurotech, Optos/Nikon, the California Institute of Regenerative Medicine; and investigator fees from Neurotech and Optos/Nikon and the California Institute of Regenerative Medicine.